Piper Sandler Companies PIPR - オプションチェーン

Piper Sandler Companies ([symbol]) オプションチェーン

オプションコール

行使価格	買値	売値	前回の価格	中間価格	建玉	最終取引
40.00	35.90	40.10	0.00	38.00	0	-
45.00	30.90	35.10	0.00	33.00	0	-
50.00	26.10	30.10	0.00	28.10	0	-
55.00	21.10	25.20	0.00	23.15	0	-
60.00	16.10	20.20	0.00	18.15	0	-
65.00	11.60	15.10	0.00	13.35	0	-
70.00	7.40	10.10	0.00	8.75	0	-
75.00	3.60	6.20	0.00	4.90	0	-
80.00	0.20	3.50	3.78	1.85	5	-
85.00	0.05	2.90	1.80	1.475	5	-
90.00	0.00	2.25	0.00	0.00	0	-
95.00	0.00	2.20	0.00	0.00	0	-
100.00	0.00	2.15	0.09	0.09	1	-
105.00	0.00	2.15	0.00	0.00	0	-
110.00	0.00	2.15	0.00	0.00	0	-
115.00	0.00	2.15	0.00	0.00	0	-
120.00	0.00	2.15	0.00	0.00	0	-

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

オプションプット

行使価格	買値	売値	前回の価格	中間価格	建玉	最終取引
40.00	0.00	2.15	0.00	0.00	0	-
45.00	0.00	1.75	0.00	0.00	0	-
50.00	0.00	2.20	0.00	0.00	0	-
55.00	0.00	2.20	0.00	0.00	0	-
60.00	0.00	2.25	0.00	0.00	0	-
65.00	0.00	1.65	0.00	0.00	0	-
70.00	0.00	2.45	0.00	0.00	0	-
75.00	0.30	2.90	0.76	1.60	1	-
80.00	2.25	6.00	3.29	4.125	1	-
85.00	5.80	8.80	0.00	7.30	0	-
90.00	11.10	13.60	0.00	12.35	0	-
95.00	15.10	19.20	0.00	17.15	0	-
100.00	20.10	24.20	0.00	22.15	0	-
105.00	25.10	29.20	0.00	27.15	0	-
110.00	30.10	34.30	0.00	32.20	0	-
115.00	35.10	39.20	0.00	37.15	0	-
120.00	40.10	44.20	0.00	42.15	0	-

銘柄コード	株価	出来高
SHPHShuttle Pharmaceuticals Holdings Inc	US$ 5.42 (43.39%)	9.85M
IVFINVO Fertility Inc	US$ 1.71 (37.90%)	5.98M
WYHGWing Yip Food Holdings Group Ltd	US$ 5.31 (34.43%)	2.07M
ILLRTriller Group Inc	US$ 3.84 (25.90%)	11.93M
INLFINLIF Limited	US$ 0.0355 (18.33%)	51.59M
CELZCreative Medical Technology Holdings Inc	US$ 1.55 (-23.65%)	138.84k
ADVBAdvanced Biomed Inc	US$ 4.00 (-19.84%)	1.42k
VBIOValion Bio Inc	US$ 0.5027 (-12.94%)	22.53k
GDCGD Culture Group Ltd	US$ 0.012 (-12.41%)	91.44M
TGHLGrowHub Limited	US$ 0.408 (-10.31%)	6.79k
GDCGD Culture Group Ltd	US$ 0.012 (-12.41%)	91.44M
INLFINLIF Limited	US$ 0.0355 (18.33%)	51.59M
NEXRNexera Technologies Ltd	US$ 1.19 (8.18%)	18.89M
ILLRTriller Group Inc	US$ 3.84 (25.90%)	11.93M
SHPHShuttle Pharmaceuticals Holdings Inc	US$ 5.42 (43.39%)	9.85M

銘柄コード

株価

出来高

GDCGD Culture Group Ltd

US$ 0.012

(-12.41%)

91.44M

INLFINLIF Limited

US$ 0.0355

(18.33%)

51.59M

NEXRNexera Technologies Ltd

US$ 1.19

(8.18%)

18.89M

ILLRTriller Group Inc

US$ 3.84

(25.90%)

11.93M

SHPHShuttle Pharmaceuticals Holdings Inc

US$ 5.42

(43.39%)

9.85M

CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure HydrocephalusJune 4, 2026 6:34 AM
PR Newswire (US) Financing led by Piper Sandler Merchant Banking, with participation from new investors Johnson & Johnson Innovation – JJDC, Inc., Johnson & Johnson's corporate venture capital arm, and MedtronicParticipation by existing investors, including Bain Capital Life Sciences and Perceptive Xontogeny Venture FundsProceeds will support the conclusion of the STRIDE pivotal trial, continued operational scale-up, advancement of regulatory work toward a future Premarket Approval (PMA) submission to the FDA, and preparations for US commercializationBoard strengthened with addition of Kevin Conroy as Lead Independent Director, Christopher Geyen as Chair of the Audit Committee, and Tom Schnettler representing Series C investorsBOSTON, June 4, 2026 /PRNewswire/ -- CereVasc, Inc., a clinical-stage medical device company developing novel, minimally invasive treatments for neurological diseases, today announced it has successfully completed the initial closing of an $85 million Series C financing. Piper Sandler Merchant Banking led the financing with participation from Johnson & Johnson Innovation – JJDC, Inc., Johnson & Johnson's corporate venture capital arm, and Medtronic, along with existing investors Bain Capital Life Sciences and Perceptive Xontogeny Venture Funds. Proceeds from the financing will fund continued clinical and regulatory development of CereVasc's eShunt System, including the ongoing STRIDE pivotal trial in patients with Normal Pressure Hydrocephalus (NPH). STRIDE is a prospective, multi-center, randomized, controlled trial designed to evaluate the safety and effectiveness of the eShunt System compared to the current standard of care, the ventriculo-peritoneal (VP) shunt, and is intended to support a future Premarket Approval (PMA) submission to the FDA. The company will also advance organizational growth and operational scale-up as it moves toward commercialization.In conjunction with the closing, the company strengthened the Board of Directors with the addition of Kevin Conroy as Lead Independent Director, Christopher Geyen as an independent director and Chair of the Audit Committee, and Tom Schnettler of Piper Sandler Merchant Banking representing the new Series C investors."This Series C financing is a meaningful milestone for CereVasc, and more importantly, for the patients who are living with conditions for which current treatment options remain inadequate," said Dan Levangie, Chairman and Chief Executive Officer of CereVasc. "This funding supports the next critical phase for the eShunt System, including PMA submission and preparation for commercial launch — accelerating our path toward a minimally invasive surgery that we believe has the potential to meaningfully improve patient outcomes and quality of life. We are delighted to welcome a slate of new investors and directors whose experience and conviction will help guide CereVasc through this next phase of growth, and we remain deeply grateful for the continued support of our existing partners."About CereVasc, Inc.
Located in Massachusetts' healthcare hub, CereVasc, Inc. is a clinical-stage medical device company focused on developing novel, minimally invasive treatments for patients with neurological diseases. Its initial product, the eShunt System, employs an innovative percutaneous transvenous-transdural approach to the central nervous system and is intended to enable the first minimally invasive treatment for communicating hydrocephalus (CH). The patented eShunt System includes an endovascularly implantable cerebrospinal fluid shunt and delivery components designed to treat CH without invasive surgery. For additional information, please visit our website at www.cerevasc.com.About Piper Sandler Merchant Banking
Piper Sandler Merchant Banking (PSMB) is the growth equity investment arm of Piper Sandler Companies (NYSE: PIPR). The PSMB team strives to partner with founders and management teams of high potential businesses that can benefit by leveraging Piper Sandler's knowledge, experience, capital and relationships to build market leading enterprises. PSMB provides investment advisory services through the affiliated registered investment adviser, PSC Capital Partners LLC. Learn more about Piper Sandler Merchant Banking.The eShunt System is an investigational device and has not been approved by FDA or any other regulatory agency for commercial sale. Its safety and effectiveness have not yet been fully established.ContactsMedia Contact:
Tiffany Weil
CereVasc, Inc.
tiffanyweil@cerevasc.com View original content to download multimedia:https://www.prnewswire.com/news-releases/cerevasc-inc-announces-over-subscribed-85-million-series-c-financing-to-advance-its-novel-eshunt-system-for-the-treatment-of-normal-pressure-hydrocephalus-302791507.htmlSOURCE CereVasc, Inc. Original: CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus